Molecular Imaging

Early FAPI-PET scans match 60-minute scans for lung cancer staging

By convention, most molecular imaging tracers such as F-18 FDG are injected one hour prior to PET scans to allow time for uptake of the tracer by tumors.

June 10, 2026

PET/CT images performed at 10- and 60-minutes following injection of Ga-68 FAPI-46 (mean 181 MBq; range 143–225 MBq).

Curium to invest €32M in French radiopharmaceutical facility

By AuntMinnieEurope.com staff writers

The investment will go toward development of a new production line for lutetium-177 PSMA-I&T, a targeted radioligand therapy.

June 1, 2026

France Flag Button 400

SNMMI: SPECT/CT tracer shows promise in interstitial lung disease

Differentiating between fibrotic scarring and inflammation stages of disease is critical so that physicians can determine what treatment is best for the patient.

May 31, 2026

Sample images from each participant group: A: CT only; B: fused Tc-99m maraciclatide SPECT/CT.

SNMMI: Machine-learning model predicts RPT dose

Dosimetry plays a central role in optimizing lutetium-177 (Lu-177) PSMA therapy, yet calculating it currently depends on post-therapy imaging.

May 30, 2026

Eye movement abnormalities flag brain health risk in ex-racing drivers

By Kate Madden Yee

A case series of 12 male retired professional motorsport drivers showed a high prevalence of mild neurological abnormalities.

May 29, 2026

Health Canada clears latest Hermia molecular imaging update

By AuntMinnie.com staff writers

The clearance allows for Hermia's clinical use across Canadian nuclear medicine and theranostics practices.

May 28, 2026

Am 2014 02 11 15 10 50 886 Canadian Flag 200 (1)

FDG-PET/CT predicts outcomes in patients with HCC

Elevated FDG uptake was consistently associated with poorer overall survival.

May 22, 2026

A graphical abstract of the study.

AuntMinnieEurope Molecular Imaging Insider

By Claudia Tschabuschnig

This edition covers the latest in PET/CT quality assurance, theranostics pipeline updates, AI in nuclear medicine, and policy developments shaping the field across Europe.

May 6, 2026

How AI can help with PET/CT guideline deviations

By Claudia Tschabuschnig

Researchers have found a gap between what international PET/CT guidelines recommend and what actually happens in clinical practice.

May 6, 2026

Pet Ct Scan Fusion Image

The EANM joins EMUC26 and pushes its policy agenda in Brussels

By Claudia Tschabuschnig

Decisions shaping who gets access to theranostics in Europe have long been made mainly in the clinic. With EANM opening a Brussels office and joining EMUC26 as co-organizer, a full policy agenda arrives at the EU table.

May 5, 2026

Serac highlights study on 99mTc-maraciclatide for endometriosis care

By AuntMinnie.com staff writers

Serac Healthcare is highlighting success from a study that evaluated the company's gamma-emitting radiotracer, 99mTc-maraciclatide.

April 30, 2026

Endometriosis 3 D Illustration 400

Lu-177 PSMA-SPECT/CT predicts survival in mCRPC

Lu-177 PSMA-617 SPECT/CT total tumor volume complete response at six weeks associated with overall survival.

April 29, 2026

Quantification of total tumor volume (TTV) at lutetium-177 prostate-specific membrane antigen (PSMA)–617 SPECT/CT shows heterogeneous TTV responses between dose 1 (Cycle #1) and dose 2 (Cycle #2) in participants with metastatic castration-resistant prostate cancer. Posttherapy coronal attenuation-corrected noncontrast SPECT/CT maximum intensity projection images demonstrate (A) near-complete response in a 76-year-old man, (B) complete response in an 83-year-old man, (C) partial TTV reduction (not complete response) in a 69-year-old man, and (D) TTV increase (i.e. progressive disease) in a 74-year-old man. Blue-shaded regions represent semiautomatically segmented PSMA-avid tumor volume, with associated TTV values given at the bottom of each panel. The gradient bar shows standardized uptake value (SUV) from 0 to 5.

Page 1 of 127